Hot Features
Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.
Inozyme Pharma Inc is a rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases of abnormal mineralization impacting the vasculature, soft tissue and skeleton. The company is focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 ... Inozyme Pharma Inc is a rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases of abnormal mineralization impacting the vasculature, soft tissue and skeleton. The company is focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies. Its product candidate, INZ-701, is a soluble, recombinant, or genetically engineered, fusion protein that is designed to correct a defect in the mineralization pathway caused by ENPP1 and ABCC6 deficiencies. Mehr anzeigen
- Positive interim results in infants and young children with ENPP1 Deficiency showed improvements from baseline in multiple measures of disease, including survival, heart function, and...
BOSTON, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage biopharmaceutical company developing innovative therapeutics for rare...
BOSTON, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage biopharmaceutical company developing innovative therapeutics for rare...
- Interim data from ENERGY 1, a Phase 1b trial of INZ-701 in infants with ENPP1 Deficiency, on track for fourth quarter of 2024 – - Topline data from ENERGY 3, a pivotal trial of INZ-701 in...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0.0599 | 4.34057971014 | 1.38 | 1.44 | 1.29 | 1230597 | 1.33696754 | CS |
| 4 | -1.6001 | -52.6348684211 | 3.04 | 3.18 | 1.29 | 940386 | 1.87114393 | CS |
| 12 | -2.8701 | -66.5916473318 | 4.31 | 4.6401 | 1.29 | 735762 | 2.56290722 | CS |
| 26 | -4.1801 | -74.3790035587 | 5.62 | 6.24 | 1.29 | 458172 | 3.35717331 | CS |
| 52 | -3.2001 | -68.9676724138 | 4.64 | 7.795 | 1.29 | 487209 | 4.47712637 | CS |
| 156 | -5.2001 | -78.3147590361 | 6.64 | 7.98 | 0.991 | 493238 | 4.15526284 | CS |
| 260 | -16.4901 | -91.9693251534 | 17.93 | 31.6499 | 0.991 | 349941 | 5.04958295 | CS |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
